Epstein-Barr Virus Infection Clinical Trials

10 recruitingLast updated: May 13, 2026

There are 10 actively recruiting epstein-barr virus infection clinical trials across 5 countries. Studies span Phase 2, Phase 1, Phase 4. Top locations include Bethesda, Maryland, United States, New York, New York, United States, Columbus, Ohio, United States. Updated daily from ClinicalTrials.gov.


Epstein-Barr Virus Infection Trials at a Glance

10 actively recruiting trials for epstein-barr virus infection are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Bethesda, New York, and Columbus. Lead sponsors running epstein-barr virus infection studies include Daihong Liu, Fudan University, and Columbia University.

Browse epstein-barr virus infection trials by phase

Treatments under study

About Epstein-Barr Virus Infection Clinical Trials

Looking for clinical trials for Epstein-Barr Virus Infection? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Epstein-Barr Virus Infection trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Epstein-Barr Virus Infection clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 1

Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection

EBVEpstein-Barr Virus InfectionInfectious Mononucleosis+1 more
National Institute of Allergy and Infectious Diseases (NIAID)750 enrolled1 locationNCT06908096
Recruiting
Phase 2

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

LymphomaEpstein-Barr Virus InfectionsLymphoproliferative Disorder+1 more
National Cancer Institute (NCI)40 enrolled1 locationNCT03258567
Recruiting
Phase 2

Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative Disorders

Epstein-Barr Virus-associated Lymphoproliferative DiseasesChronic Active Epstein-Barr Virus InfectionEBV Associated Lymphoma+1 more
Fudan University80 enrolled2 locationsNCT07381738
Recruiting
Phase 1Phase 2

Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation

Post-Transplant Lymphoproliferative DisorderEpstein-Barr Virus Infection
Daihong Liu18 enrolled1 locationNCT07368634
Recruiting
Phase 1Phase 2

Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity

Epstein-Barr Virus InfectionsCytomegalovirus InfectionsAdenovirus
Jessie L. Alexander25 enrolled3 locationsNCT06909110
Recruiting
Phase 2

EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

Epstein-Barr Virus InfectionsPrimary Immune Deficiency Disorder
New York Medical College20 enrolled8 locationsNCT03266653
Recruiting
Phase 1Phase 2

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Advanced Solid TumorsCarcinomaNeoplasms+9 more
Marengo Therapeutics, Inc.365 enrolled32 locationsNCT05592626
Recruiting
Phase 1

R-MVST Cells for Treatment of Viral Infections

Epstein-Barr Virus InfectionsCytomegalovirus InfectionsBK Virus Infection+1 more
Columbia University36 enrolled1 locationNCT05183490
Recruiting
Phase 4

Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft

Epstein-Barr Virus Infections
University Hospital, Strasbourg, France120 enrolled1 locationNCT04989491
Recruiting

Evaluation of CMV/EBV-CMI in Haploid HSCT

Epstein-Barr Virus InfectionsHematopoietic Stem Cell TransplantationCytomegalovirus Infections
The First Affiliated Hospital of Soochow University60 enrolled1 locationNCT06554197